HER2 is overexpressed mainly in breast cancer but also in gastrointestinal, ovarian, and bladder cancer, and is associated with a highly aggressive infiltrating type of tumor prone to metastatic spreading (Iqbal and Iqbal, 2014). Here, ERBB2 is linked to neoplasm.